Our Latest News - BUHLMANN

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important

Basophils Are Still Alive

Quality Assay & Sample Stability for Viable Basophils Basophil Activation Testing (often referred to as BAT) is a flow-cytometry-based functional assay that assesses the degree of cell activation after exposure to stimuli.3 Q: Do you know which BAT application makes sense for your lab? Are you thinking about implementing an allergy BAT? Or are you

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

BÜHLMANN fCAL® ELISA Citation Foster, A. et al. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients. World J Gastroenterol. PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266. Highlight from this Publication ..."Notably, in keeping with adult IBD practice, our study shows that children should also have FC levels checked every 3 mo to ensure adequate monitoring."… Read Citation BÜHLMANN

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s

Two New fCAL turbo Video Testimonials from Portugal

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Unilabs Portugal, a private European lab chain, made a comprehensive evaluation of different Calprotectin assays on the market and found many discrepancies with assays from other suppliers. Finally, they chose the BÜHLMANN fCAL® turbo simply because it

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

IBDoc® Citation: Wei, S. , Tung, C. et al. Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring. Intestinal Research 2018;16(4):546-553. DOI: https://doi.org/10.5217/ir.2018.00052 PMID: 30301339 Highlights from this Publication “96% of the patients were satisfied with the home test..." “71% of patients preferred the home test method monitor

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc® Citation: Walsh, A, Kormilitzin, A et al. Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis—a Prospective Analysis, Journal of Crohn's and Colitis, jjy184, PMID: 30445625 DOI: doi.org/10.1093/ecco-jcc/jjy184 Highlights from this Publication “This is the first prospective study to use validated endoscopic and histologic indices to determine the thresholds of

IBDoc Canadian User Performance Evaluation

IBDoc® Citation: Alice C Moore, Vivian W Huang, Raymond Bourdages, Richard N Fedorak, Christian Reinhard, Yvette Leung, Brian Bressler, Greg Rosenfeld; IBDoc Canadian User Performance Evaluation, Inflammatory Bowel Diseases, , izy357, DOI: https://doi.org/10.1093/ibd/izy357 PMID: 30535387 Highlights from this Publication "The majority of patients found it easy-to-use and felt that most patients would be able to learn how to

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,” Associate Professor

BUHLMANN News

Educational Webinar- Calprotectin in the Diagnosis of Inflammatory Bowel Disease

Basophils Are Still Alive

Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

Two New fCAL turbo Video Testimonials from Portugal

Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring

Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis

IBDoc Canadian User Performance Evaluation

Clinical Trial Combines New Symptom App with IBDoc

ABOUT US

SOCIAL MEDIA

QUICK LINKS

CONTACT US